Unfortunately (fortunately?) I'm not an accountant - just a lawyer - so my GAAP knowledge is limited. I agree with your hypothesis but can't give a definitive answer. I'd expect (obviously) more equity grants as the R&D team grows - Tesla seems to grant awards quite deep into the organization whereas many other companies only do, e.g., VP and above - but I don't know enough about accounting rules to understand how this is allocated between G&A/R&D, etc. I think it's technically R&D as stock-based compensation line item (but not 100% positive), meaning that R&D expenses would grow, but I'd expect this to be a small drop in the bucket compared to "real" R&D costs. Shouldn't scale linearly at all.I agree with your comment 100%. Thank you for following up.
Also, since you seem to have at least a few years of practical accounting experience, could you please enlighten us on the following:
I spent some time in accounting, but that was years ago and the rules may have changed. Would you expect Tesla's R&D expense to show a step-change increase as revenue ramps up (i.e. because of GAAP), or would the increase be more correlated with how many engineers Tesla hires as part of an ongoing usual ramp in R&D expense? In other words, just like depreciation will be somewhat correlated with cars produced as Tesla uses units of production method of depreciation (i.e. depreciation will show a step-change up in 1H18), is R&D expense also correlated at all with number of cars produced solely because of GAAP (i.e. are any R&D costs capitalized for revenue matching)?
I suspect the answer is no, but I wanted to confirm.
Thank you in advance.